Glaxo Smith Kline responded to 3 billion tickets: obey the judgments of the judiciary | Glaxo Smith Kline, China _ news

Shanghai, September 19 Reuters new media (reporter Zhou Lin) regulators out of the 3 billion-yuan ticket for Glaxo Smith Kline Corporation posted 19th apologized in a statement, fully recognizes China's judicial organs in accordance with findings of fact and evidence, and obedience to lawful judgment of the Chinese judicial authorities.

Said in a statement, China's judicial authorities after a thorough investigation, identified by Glaxo SmithKline China company to seek illegitimate interests, to non-State property, constituted non-State agents of bribing.

Glaxo Smith Kline Corporation, fully agree with China's judicial organs in accordance with findings of fact and evidence, subject to lawful judgment of the Chinese judicial authorities, and extended to the patients, doctors, hospitals and the Chinese Government, the Chinese people profound apology for the damage and Glaxo Smith Kline Corporation are deeply saddened and ashamed. Due to illegal investigations by Glaxo SmithKline China companies harmed by the persons concerned, Glaxo Smith Kline Corporation also apologize.

Said in a statement, Glaxo SmithKline China company of similar grave violations against Glaxo Smith Kline Corporation's rules and regulations, radically departed from the company require employees to comply with the values and code of conduct. The behavior wasn't found in time and are stopped, Glaxo Smith Kline Corporation deeply regrets. Glaxo Smith Kline Corporation has deep introspection, and learn from it, has taken concrete measures to overhaul of Glaxo SmithKline China's problems in the operations of the company, to make every effort to regain the trust of the Chinese people.

Meanwhile, Glaxo Smith Kline Corporation promises, Glaxo SmithKline China will take practical action to establish a model for reform in the pharmaceutical industry in China: will insist on continued investment in China, and, as always, support China's development of science and technology; diseases will be popular in China, to further promote research and development of drugs and vaccines. Glaxo Smith Kline firms by boosting production in China, the expansion of drug prices to fall space, China's rural areas and cities, improve the accessibility of Glaxo Smith Kline pharmaceuticals.

Changsha intermediate people's Court of Hunan province 19th in accordance with the Glaxo Smith Kline (China) investment company limited and others, including Ma Kerui permissible for non-State, non-State staff bribery case to public hearing and publicly on the same day. Glaxo Smith Kline was sentenced to a fine of 3 billion yuan, which is by far the largest in China tickets, Ma Kerui, a defendant is sentenced to 2-3 years. (End)

(Edit: SN123)
17:39 on September 19, 2014
Xinhua News Agency